**Core tip:** Type 1 diabetes (T1D) is one of the most common childhood chronic conditions with its incidence increasing annually. Its arduous management requires vigilance to avoid complications that impact quality of life and health care costs. A better understanding of how T1D develops can help find a way to prevent it from developing at all. In this review, we discuss the current understanding of the complex relationship between the roles of genetics and the environment in the development of T1D.

INTRODUCTION
============

Type 1 diabetes (T1D) is one of the most common childhood chronic conditions. Though its peak incidence is between the ages of 10 and 14, its clinical presentation can occur at almost any age from early infancy to as late as the 9^th^ decade of life\[[@B1]-[@B3]\]. See Figure [1](#F1){ref-type="fig"}\[[@B3]\], for the relative incidence at different age groups. Data from large epidemiologic studies worldwide have indicated that the incidence of T1D has been increasing by about 2%-5% worldwide annually and that the prevalence of T1D has increased to approximately 1 in 300 in the United States by 18 years of age\[[@B1]\]. It affects 2.28 in 1000 children as compared to the 1.24 of 1000 youths (\< 20 years old) affected by cancer and 120 of 1000 youths suffering from asthma\[[@B1],[@B4]\]. Additionally, T1D can significantly affect the quality of life of patients and families because they are required to vigilantly monitor their blood sugars with needled lancets or other monitoring devices and administer insulin with syringes, pens, or insulin pumps several times a day. Moreover, there is a significant public health impact with an estimated total cost of \$132 billion in the United States in 2002\[[@B4],[@B5]\].

![Incidence of type 1 diabetes in the United States by age.](WJD-11-13-g001){#F1}

The high number of people affected by T1D and its health burden has spurned a robust growth of clinical research aimed at improving the quality of life of those affected and basic research looking at ways to better understand the pathogenesis of this disease in the quest for a cure. Though significant advances have been made, there is still much we do not understand about what triggers T1D and how to effectively control this disease, and thusly much research work is still needed. This review article will focus on our current understanding of the development of T1D from an immunologic, genetic, and environmental standpoint. We will highlight promising and interesting studies that seem closest to uncovering why and how T1D develops.

HIGHLIGHTS OF PATHOGENESIS OF T1D
=================================

Diabetes mellitus (DM) is a condition characterized by a state of relatively insufficient or complete lack of insulin production. There are various types of DM that include: T1D, T2D, gestational, post-pancreatectomy, Mature Onset Diabetes of the Youth, neonatal diabetes, and medication-induced diabetes. T1D "contributes up to about 10% of the estimated 422 million diabetes cases worldwide"\[[@B6]\].

T1D results from the destruction of the insulin-producing cells in the pancreas called beta cells by the adaptive immune system. This process is promoted by an incompletely understood interaction between a person's genetics and their environment. Genetic factors (*i.e*., individuals with an overexpression of human leukocyte antigen or HLA class molecules DR4, DQ8, and DQ2 increasing their susceptibility is present in approximately 90% of T1D patients) and one or more environmental factors lead to the recognition of beta cell components as autoantigens that the immune system erroneously recognizes as foreign leading to an autoimmune attack\[[@B1],[@B7],[@B8]\]. Identified autoantigens include insulin B chain peptide (11-23) and other components of beta cell secretory granules such as glutamic acid decarboxylase 65, protein phosphatase-like IA-2, and transmembrane Zn transporter. The presence of one known autoantibody confers a moderate risk of developing T1D while the presence of each additional autoantibody increases the risk exponentially\[[@B7]\].

These autoantigens are presented by HLA molecules major histocompatibility complexes (MHC) I and II on antigen presenting cell (APCs) to diabetogenic autoreactive T cells. Autoreactive CD4 T cells stimulate APCs, including B cells that produce high-affinity autoantibodies against beta cells. Autoreactive CD4 T Cells also help diabetogenic CD8+ T cells to acquire cytolytic activity and attack beta cells through the release of cytokines (including TNF-α and IFN-γ, Fas/FASL and perforin/granzyme). Released cytokines also stimulate macrophages and other innate immune cells to further damage beta cells yielding a positive feedback loop with the production of more toxic cytokines to propagate further beta cell destruction\[[@B7],[@B8]\].

There has been much debate regarding the identity of the nidus that initiates the autoimmune destruction of beta cells. Other groups are currently studying potential players in the immune system such as FasL B cells and dual expresser (DE) cells that may play a role in T1D pathogenesis. Using Flow Cytometry, high-throughput sequencing, and transcriptional analysis utilizing RNA-seq, interesting subsets of CD5+ B Cells that include IL-10 producing B-reg cells, FasL-expressing B cells and DE cells that express both B cell receptor (surface immunoglobulin, Ig) and T cell receptor have been discovered\[[@B9]\]. Findings suggest that the CDR3 region of the heavy chain of surface Ig on the DE cell expresses an extremely potent diabetogenic T-cell autoantigen that is able to stimulate other T cells and may contribute to the development of T1D and similarly potent x-autoantigens with different CDR3 sequences could be involved in pathogenicity of other autoimmune diseases\[[@B10]\]. Another study also suggests that T1D could be caused by a paucity of anti-inflammatory IL-10-producing Breg cells by apoptosis mediated by FasL expressing B cells leading to the unchecked proliferation and expansion of diabetogenic T cells\[[@B11]\]. This is supported by the elevated levels of FasL-expressing CD5+ B cells in the splenocytes and lymph nodes of T1D patients compared to controls and the prevented development of T1D in non-obese diabetic (NOD) knockout mice or mice treated with FasL-neutralizing monoclonal antibody\[[@B11]\]. Further studies are being performed to determine the significance of blocking FasL in humans and targeting DE cells as a form of immunotherapy.

ROLE OF GENETICS IN T1D
=======================

T1D is a multifactorial disease that is affected by a number of genes. Even in the case of high-risk conferring haplotypes that are present in 90%-95% of T1D children, only 5% or fewer with the haplotype actually develop overt T1D in the general population\[[@B1]\]. This supports the fact that there must be other factors, genetic, epigenetic, and/or environmental that play a role in ultimately determining disease manifestation. According to genome wide association studies, over 60 genes can affect the risk of the developing T1D especially those that affect the HLA loci\[[@B12],[@B13]\]. Up to 30%-50% of the genetic risk in T1D is related to HLA class II alleles. Of the HLA class II genes, the mutations found on the HLA region of chromosome 6p21 have been shown to be a major susceptibility locus for T1D. There are also several non-MHC loci that have a lesser contribution to disease risk, such as IFIH1, IL2RA, PTPN22, and CTLA4\[[@B13]-[@B15]\]. See Table [1](#T1){ref-type="table"} for a list of prevalent T1D-associated genes associated with risk factors\[[@B16],[@B17]\] and protective factors\[[@B18],[@B19]\].

###### 

Genetic risk and protective factors of type 1 diabetes[1](#T1FN1){ref-type="table-fn"}

  **Risk factors**\[[@B16],[@B17]\]              **Protective factors**\[[@B18],[@B19]\]
  ---------------------------------------------- -----------------------------------------
  HLA DR3/DQ2                                    DRB1\*15:01
  HLA-DR4/DQ8                                    DQA1\*01:02
  HLA-A\*02:01                                   DQB1\*06:02
  Increased PTPN22 activity                      Rare variant of IFIH1
  INS polymorphisms                              
  IL2RA variants                                 
  Increased expression of common variant IFIH1   
  1^st^ degree relative with T1D                 

These genetic factors represent more prevalent risk factors associated with type 1 diabetes and is not all inclusive. PTPN22: Protein tyrosine phosphatase non-receptor type 22; INS: Insulin gene; IL2RA: Interluekin-2 receptor alpha; IFIH1: Interferon-induced with helicase C domain 1; T1D: Type 1 diabetes.

Interestingly, although the association of T1D with the HLA class II genes DQ and DR has been well validated, individuals who are heterozygous for HLA-DRB1\*04 and HLA-DRB1\* 03 type have been found to be at highest risk\[[@B14]\]. It has been suggested that almost 50% of children with the HLADR3/4-DQ8 heterozygous genotype will develop anti-islet autoimmunity before the age of 5\[[@B14],[@B15]\]. Children with the DR3/4-DQ8 or DR4/DR4 homozygous genotype and a family history of T1D have more than a 1 in 5 risk to developing islet autoantibodies, whereas children with no family history and DR3/4-DQ8 or DR4/DR4 genotype have a 1 in 20 risk\[[@B15]\].

Therefore, it stands to reason that HLA typing could be a cost-effective method to screen for T1D susceptibility and identify high risk individuals at an early age if targeted immunotherapy is available to prevent disease onset. There are many ongoing international projects, including DIPP, TEDDY, TRIGR, and TrialNet that are monitoring high-risk individuals, their risk alleles and their progression to T1D to better elucidate the positive and negative predictive values of identifying the presence of high-risk alleles. Thus far, it is clear that the inheritance of T1D is complex and development of overt disease involves both a genetic predisposition and an environmental trigger(s) since the presence of high-risk genetic determinants does not yield a 100% positive predictive value.

The strong multifactorial genetic component of T1D is further supported by the effects of familial inheritance. Interestingly, the offspring of mothers with T1D have a reduced risk of developing T1D when compared to the offspring of fathers with T1D. Harjutsalo's group's study of at-risk (offspring of T1D patients) Finnish children found that the risk of developing T1D was 1.7 times higher if the father had T1D as compared to when the mother had T1D (incidence of 7.8% vs 5.3%, respectively)\[[@B20]\]. They also found that sons (more than daughters) of a parent with T1D had an increased risk of developing T1D. A younger age of the male parent (at diagnosis) was also found to be a significant predictor with fathers diagnosed at the age of ≤ 4 years being 2.66 times more likely to have children with T1D than fathers diagnosed at the age of 15-17 years\[[@B20]\].

The reason why mothers with T1D are less likely to pass on T1D to children than fathers with T1D remains unclear. Some hypothesize that it may be caused by selective loss of fetuses in mothers with T1D since the rate of miscarriage is higher (15%-30%) in T1D mothers than the general population usually as a result of hyperglycemia at conception and early pregnancy\[[@B21]-[@B23]\]. Others hypothesize that it may be due to upregulation of CD4+CD25+FOXP3+ Treg cells that have been found to be significantly elevated in the offspring of mothers with T1D in comparison to infants of healthy mothers\[[@B24]\]. In addition, studies have found that children born before maternal onset of T1D have a higher risk of T1D than infants born after maternal disease onset. Their studies also showed that in vitro insulin stimulation of CD4+CD25+ cells upregulated the expression of anti-inflammatory genes and FOXP3 + Treg cells suggesting that insulin treatment of T1D mothers during pregnancy increases the expansion of anti-inflammatory regulatory cells in their offspring thereby decreasing their risk of T1D development as compared to the offspring of fathers with T1D\[[@B24]\].

TWIN STUDIES AND EPIGENETIC MODIFICATION
========================================

Studies in twins have demonstrated the important role of gene and gene modification in the development of T1D. Dizygotic (non-identical) twins and siblings share about 50% of their genes, while monozygotic or identical twins share 100% of their genes meaning differences found between monozygotic twin pairs are likely the result of environmental factors or post-translational modification of histones, the activation of microRNAs, the methylation of DNA, or acquired postconceptional genetic discordance. Multiple studies indicate a significantly higher concordance rate for T1D in monozygotic twins than dizygotic twins (23%-61% *vs* 0-27% probandwise, respectively). Table [2](#T2){ref-type="table"} compares the concordance rates of a co-twin developing T1D when there is a proband twin diagnosed with T1D. In addition, it was noted that "more monozygotic twins were positive for \> 1 autoantibodies that dizygotic twin siblings"\[[@B25]\]. A study followed siblings for 3 years after screening for autoantibodies to see how many would develop T1D and showed that the T1D rate increases with the increasing number of autoantibodies present in the co-twin when the proband twin had been diagnosed with T1D\[[@B26]\]. It also showed that a larger proportion of monozygotic twins are likely to have positive antibodies than dizygotic twins or full siblings\[[@B26]\], see Table [3](#T3){ref-type="table"}. Interestingly, a North American study also found that the relative risk of developing TID increased if the proband was diagnosed at an earlier age. It noted that "if the proband is diagnosed before 15 years of age, the long-term risk to the co-twin is estimated at 44% (monozygotic) and 19% (dizygotic); it reaches 65% for the co-twin of a monozygotic proband diagnosed before 5 years of age with time after the proband's diagnosis"\[[@B27]\]. Additionally, the discordance time among the concordant could range from 1-36 years\[[@B25],[@B28]\] with the mean time being 3.3 (+/- 0.6) years for monozygotic twins and 6.1 (+/- 1.5) years in dizygotic twins\[[@B27]\]. This suggests that while genetics play an important role in the ultimate development of T1D, there must be other factors that contribute since the concordance rate is not 100%.

###### 

Concordance rate of monozygotic and dizygotic twins in the indicated countries

  **Study population**                           **Relation**   **No. of twin pairs**   **No. of concordant pairs**            **Probandwise concordance rate (%)**
  ---------------------------------------------- -------------- ----------------------- -------------------------------------- -------------------------------------------
  Australia\[[@B95]\]                            Monozygotic    14                      6                                      61
  Dizygotic                                      32             2                       12                                     
  Finland\[[@B28]\]                              Monozygotic    44                      12                                     42.90
  Dizygotic                                      183            7                       7.40                                   
  Japan\[[@B96]\]                                Monozygotic    19                      7                                      53.8[1](#T2FN1){ref-type="table-fn"}
  Dizygotic                                      13             1                       14.3[1](#T2FN1){ref-type="table-fn"}   
  United States\[[@B25]\]                        Monozygotic    53                      12                                     36.9[1](#T2FN1){ref-type="table-fn"}
  Dizygotic                                      30             0                       0                                      
  Denmark\[[@B97]\]                              Monozygotic    26                      10                                     53
  Dizygotic                                      69             4                       11                                     
  Finland\[[@B98]\]                              Monozygotic    26                      3                                      23.10
  Dizygotic                                      83             2                       4.80                                   
  North America\[[@B27]\]                        Monozygotic    132                     38                                     45
  Dizygotic                                      92             13                      25                                     
  United Kingdom\[[@B99]\]                       Monozygotic    49                      15                                     25 (1 yr)[1](#T2FN1){ref-type="table-fn"}
  40 (5 yr)[1](#T2FN1){ref-type="table-fn"}                                                                                    
  50.7 (10 yr)[1](#T2FN1){ref-type="table-fn"}                                                                                 

Rate not listed in original study, but calculated here based on the equation (2C/2C+D), where C is the number of concordant twin pairs and D is the number of discordant twin pairs.

###### 

Progression to type 1 diabetes in siblings within 3 years based on number of autoantibodies at screening

  **Relation**        **0 Autoantibodies**   **1 Autoantibody**   **≥ 2 Autoantibodies**               
  ------------------- ---------------------- -------------------- ------------------------ ----- ----- -----
  Monozygotic Twins   89                     1.50%                25                       69%   29    69%
  Dizygotic Twins     231                    0%                   22                       13%   17    72%
  Full Siblings       13944                  0.50%                1456                     12%   900   47%

T1D: Type 1 diabetes.

To address this issue, some have looked to epigenetic factors such as DNA methylation, which is important in gene expression and transcriptional regulation. Rakyan's group performed an epigenomic-wide association study looking at DNA methylation profiles from T1D monozygotic discordant twin pairs and diabetes-associated antibodies from longitudinally sampled pre-and post-diagnosis T1D singletons to identify CpG sites with T1D-MVPs (T1D-associated methylation variable positions), genetic differences, and epigenetic variations. In this manner, they identified a number of genes including INS-IGF2, SH2B3, MEG3 and ORMDL3, that are known to be correlated with T1D and had differential CpG methylation when they compared T1D-affected to non-affected twins\[[@B29]\]. This demonstrates that in addition to inheritance and the presence of risk genes/alleles, epigenetic factors (such as DNA methylation or exposure to insulin in utero) that regulate gene expression or upregulated anti-inflammatory cells could determine whether T1D would develop.

ROLE OF THE ENVIRONMENT
=======================

Though many genetic factors have been implicated in the development of T1D, it's widely believed that environmental factors must be involved. Genetic susceptibility persists for a lifetime. Individuals can develop T1D at any time from age 1 to 100 years old suggesting that "T1D precipitates in genetically susceptible individuals, very likely as a result of an environmental trigger"\[[@B1],[@B14]\]. This is also supported by the temporally discordant times of T1D development (if at all) in monozygotic twins. Several environmental factors have been suggested as potential risk and protective factors\[[@B30],[@B31]\] affecting T1D incidence such as viruses, anthropometric development\[[@B32]-[@B34]\], ethnicity, maternal age and weight\[[@B35]\], microbiota\[[@B36]-[@B38]\], number of siblings\[[@B35]\], season, diet, and geographic location\[[@B18],[@B31]\] among other factors. See Table [4](#T4){ref-type="table"} for a list of environmental factors likely contributing to T1D development.

###### 

Environmental risk and protective factors of type 1 diabetes

  **Risk factor**                                              **Protective factors**
  ------------------------------------------------------------ ------------------------------------------------
  Group B Coxsackieviruses\[[@B42],[@B44],[@B45]\]             Longer breastfeeding duration\[[@B78]-[@B80]\]
  Early introduction of cow's milk duration\[[@B76],[@B77]\]   Vitamin D intake supplements\[[@B68],[@B69]\]
  Early cereal introduction\[[@B72],[@B87]\]                   Polyunsaturated fatty acids\[[@B89],[@B90]\]
  High latitudes\[[@B18],[@B31]\]                              Intestinal microbiome\[[@B36]-[@B38]\]
  Cold seasons\[[@B55]-[@B57]\]                                Multiple living siblings\[[@B35]\]
  Acceleated linear growth and weight gain\[[@B32]-[@B34]\]    
  White ethnicity\[[@B35]\]                                    
  Maternal age \> 35 yr\[[@B35]\]                              

Viruses
-------

Of the external factors, viruses have long been suggested as a potential environmental trigger for the disease and has some of the strongest evidence as a potential factor. Though there has been strong evidence to suggest the association of viruses with T1D, evidence of a definitive causative relationship leading to the initiation or acceleration of islet autoimmunity is circumstantial\[[@B39]-[@B41]\]. Viral infection by enteroviruses such as coxsackieviruses (CVB) or echoviruses have been strongly implicated as potential disease triggers. Several epidemiological studies have linked the association of CVB infection with T1D onset. One study performed between 1964-1984, found that among children diagnosed with T1D, 67% of them had positive CVB IgM serology\[[@B42]\]. Similarly, among 14 children presenting with new-onset T1D, 64% of them were found to have serologic evidence of enteroviral infection, which were mainly CVB3 and CVB4\[[@B43]\]. CVB1 was found to increase the risk of developing T1D in studies looking at children who were at high risk or recently developed T1D\[[@B44],[@B45]\].

The exact mechanism by which viral infections contribute to the destruction of islet cells is still unknown. However, various mechanisms have been suggested such as molecular mimicry, inflammation, endoplasmic reticulum (ER) stress, and bystander activation or suppression of T cells, which are detrimental to beta cell function and survival\[[@B30],[@B31]\]. Some studies have reported cross-reactivity between islet cell autoantigens and certain viral proteins. However, there is no proof that this cross-reactivity leads to T1D autoimmunity\[[@B30]\]. Interestingly, at-risk children with insulin autoantibodies have a reduced ability to produce antibodies to VP1 (markers of viral infections), possibly facilitating enterovirus infection and persistence\[[@B46]\]. It was found that inflammation and ER stress induced by viruses can cause beta cell dysfunction and protein misfolding, which could lead to an abnormal presentation of autoantigens and thus to autoimmunity\[[@B47],[@B48]\]. Viral infection can also stress the ER causing beta cells to release exosomes loaded with autoantigens and immuno-stimulatory chaperones, which are then taken-up by APCs\[[@B30],[@B49]\]. These can then be presented to the adaptive immune system and cause beta cell destruction.

Such associations have also been found in experimental mouse models. One study was able to induce diabetes in mice using a coxsackie virus (CVB4E2) isolated from a patient with diabetic ketoacidosis\[[@B50],[@B51]\]. Additionally, coxsackievirus infection has been found to escalate the progression of T1D in mice engrafted with human islets\[[@B52]\]. Transfer of CVB-specific antibodies from mothers to their offspring in NOD mouse models decreases the risk in the offspring for CVB infection and protects them from T1D development\[[@B53],[@B54]\]. However, a conclusive link between viral infection and the onset of T1D in humans is still lacking. While mouse models have shown a potentially causative relationship between viruses and T1D development, there have mostly been epidemiological studies in humans and no conclusive trials to establish a causative link. However, if a viral link were confirmed, it would garner support for research to develop an enterovirus vaccine to help prevent T1D.

Seasonality
-----------

Interestingly, studies have revealed that migrants tend to develop the same level of risk of developing T1D as the population in the area of their new residence, despite their origin being from a low incidence region of the world. This supports the theory of the environmental effects of T1D development, which could be influenced by factors such as seasonality or geographic location.

Numerous reasons have been proposed for the apparent link between seasons and the onset of T1D. Some of these theories include that there is a seasonal variation in the blood glucose and insulin levels possibly due to a typically reduced level of activity in young people in the cold winter months and seasonal viral infections. Several studies suggest a seasonality that conforms to a sinusoidal model that peaks in the winter and troughs in the summer\[[@B55],[@B56]\]. Epidemiological studies following birth cohorts found that many people (79%) with high risk genotypes seroconverted during the fall/winter months\[[@B57]\]. A large international study found that 42 out of 105 centers exhibited this seasonal trend with 28 centers having peaks of diagnosis in the winter and 33 had troughs in the summer\[[@B58]\].

However, other studies contradicted this correlation, stating that their findings indicated that there was no seasonality in the month of onset, rather that there was significant seasonality in the month of birth (peaking in November to January)\[[@B59]\]. In addition, the seasonality pattern appears to be dependent on the geographical position, in regards to the northern/southern hemisphere dichotomy. The correlation of seasonality appeared to disappear after adjustment was made for latitude, where centers furthest away from the equator were more likely to exhibit significant seasonality\[[@B58]\]. However, most of the data from the study came from the northern hemisphere, and there was inadequate information from Asia and Africa. Therefore, this correlation was deemed inconclusive, as more data on the population living below the 30th parallel north was needed for the information to be accurate\[[@B58]\]. Though still inconclusive, this data likely indicates that there is an increased susceptibility to developing T1D during times when people are most vulnerable to viral infections. This is generally during cold (viral infection) seasons, which may vary based on geographic location and could explain why regions in colder climates or with temperate seasons have higher T1D incidence rates than regions with warmer climates and tropical seasons.

Vitamin D
---------

There is increasing evidence that demonstrates a strong association between vitamin D signaling and many biological processes involved in regulating immune responses. A deficiency in vitamin D is associated with increased risk of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and T1D\[[@B60]\]. The vitamin D receptor (VDR) is expressed on several immune cells (B cells, T cells and antigen-presenting cells) and affects "cell proliferation and differentiation and immunologic effects resulting in an ability to maintain tolerance and promote protective immunity"\[[@B61]\].

FokI (rs10735810) has been identified as one of four polymorphisms in the VDR gene. Its presence has been suggested to cause a dysfunctional structural change on the VDR protein\[[@B62]\]. Studies demonstrated that mononuclear cells from subjects with the dysfunctional VDR genotype had a lower ED50 of 1,25 (OH)2D when compared with the normal VDR genotype\[[@B63]\]. Studies also reported that monocytes and dendritic cells from subjects with the dysfunctional genotype had a higher expression of interleukin-12 (pro-inflammatory cytokine) and proliferated more significantly after stimulation than those with the normal genotype\[[@B64]\].

A causal relationship between FokI polymorphism and vitamin D status in T1D has not been reported, but several studies have suggested a correlation. Vitamin D deficiency has been found to be higher in children with T1D in comparison to controls\[[@B65]-[@B67]\]. A birth cohort following over 12000 live births found that children receiving regular Vitamin D supplementation had a reduced risk of developing T1D with a RR of 0.22 (0.05-0.89), while children suspected of rickets (related to vitamin D deficiency) had a RR of 3.0 (1.0 -9.0) of developing T1D\[[@B68]\]. Another study involving patients with latent auto-immune diabetes found that c-peptide levels and beta cell function was better preserved in the group who received vitamin D supplements\[[@B69]\]. Some aspects regarding the relationship of islet autoimmunity and development of T1D remain controversial. Though still controversial, vitamin D appears to have a beneficial effect in preventing T1D, likely due to its role in modulating potentially pathogenic inflammatory processes.

Diet
----

Epidemiological studies have noted that a majority of children that develop T1D before the age of 10 years old, seroconvert within the 1st two years of life\[[@B57]\]. This suggests that early life exposures could play an important role in environmental factors leading to T1D such as nutrition and diet.

Dietary factors that have been explored include infant food exposures such breastfeeding, cow's milk formula, and cereal. Their role in the development of T1D is controversial with a number of studies having conflicting conclusions and insufficient evidence to prove a causal effect\[[@B70]-[@B74]\]. However, a majority of birth cohort studies investigating high-risk infants indicate that short durations of breastfeeding (earlier than 2-4 mo)\[[@B75]\] and early introduction of cow's milk (earlier than 4 mo)\[[@B76],[@B77]\] may have a predisposing factor with an overall odds ratio of 1.43 (95%CI: 1.15-1.77) and 1.63 (95%CI: 1.22-2.17), respectively\[[@B78]\]. While a longer duration of exclusive breastfeeding (longer than 4 months) has a protective factor with an odds ratio of 0.17, 95%CI: 0.03-0.86\[[@B75]\]. The exact mechanism for these predispositions are still speculative. It is proposed that breastfeeding provides the benefit of additional immune protection from the passing of maternal antibodies that may help decrease the frequency of early enteroviral infections\[[@B79],[@B80]\] and decreased intestinal permeability, which may protect from potentially T1D inciting exposures\[[@B81]\]. The predisposition caused by early exposure to cow proteins is thought to be mediated by inflammation of the intestinal mucosa\[[@B82]\], increased intestinal permeability\[[@B81]\] and a dysregulated immune response to the milk proteins\[[@B83]-[@B85]\]. Intertwined with this concept is the role of intestinal microbiome. Intestinal "microbes influence lipid and glucose metabolism, as well as immunity and systemic inflammation outside of the intestine"\[[@B86]\]. Available studies on this subject are currently inadequate to confirm a definitive connection, but there appears to be a trend of lower microbial diversity in people with T1D with a dominance of a microbiome less conducive to maintaining gut integrity\[[@B86],[@B87]\].

Another study looking at exposure to cereal found that initial cereal exposure before 4 mo of age\[[@B72]\] and after 6 mo of age was associated with an increased risk of T1D or islet autoimmunity with a HR = 5.55 (95%CI: 1.92-16.03) and 12.53 (95%CI: 3.19-49.23), respectively\[[@B88]\].

Another dietary factor that has been investigated is the effect of polyunsaturated fatty acids diets, given its association in modulating the immune system and curtailing inflammatory responses\[[@B89],[@B90]\]. An observational study in the United States found that omega-3 fatty acid intake was inversely associated with the risk of developing T1D or islet autoimmunity\[[@B91]\]. Another study noted linoleic acid had an inverse, marginal association with the development of T1D\[[@B92]\]. Conversely, other studies have found no correlation between fatty acids and islet autoimmunity. It is also interesting that some regions (*i.e*., India or Africa) that have relatively low polyunsaturated fatty acids in their diet do not necessarily have high T1D incidence rates. This could be because these fatty acids do not play a major role as an environmental factor, increase intake confers a protective factor, but its lack does not yield a risk factor. It could also be possible that other factors such as geography offset these possible risk factors.

CONCLUDING THOUGHTS
===================

Some of the first cases ascribed to T1D were discovered by the ancient Indians around 1500 BC when patients were noted to have excessive urination that would attract ants due to its sweetness\[[@B93]\]. This condition had been recognized later as a disease and eventually given the name T1D. Early on, T1D was a death sentence because no one understood the pathogenesis or could manage it. Those affected would suffer from insatiable hunger and slowly waste away and die from acute complications. After the seminal discoveries by Joseph von Mering and Oskar Minkowski in 1889 of the pancreas' role in T1D and Frederick Banting and Charles Best ability to purify insulin (in the 1920s) from animal pancreas for the use in treatment of T1D patients, life with diabetes has become an issue of management and not certain death\[[@B94]\].

Since then, significant progress has been made in understanding T1D as a disease with a multifactorial etiology, including genetic factors, primarily affecting the adaptive immune system, and environmental triggers. However, our understanding of T1D pathogenesis remains incomplete. There are still many questions such as why particular genetic variants predispose to the disease, how epigenetics and environmental factors contribute to the disease onset (especially given the 40%-60% disconcordance rate in identical twins), and whether other unrecognized genetics and/or immunologic factors play a pivotal role in T1D development and progression (*i.e*., DE cells or FasL)\[[@B10],[@B11]\].

Answering these questions is urgently needed as patients still suffer from reduced quality of life given the large treatment burden, the risk of life-threatening hypoglycemia and potentially debilitating end organ complications. Current research focusing on these parameters to clarify the pathogenesis of this disease are expected to help in the development of novel treatments that could prevent disease onset or slow progression by identifying new targets for immunotherapy or vaccines to prevent its initiation. Overall, while the battle against T1D is still ongoing, research has provided us the tools to gain an upper hand and the knowledge to hopefully win the battle in the early stages or before it has begun.
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